Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of 6855.HK is 97 and suggests 123% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell